Skip to main content

Table 8 Proteinuria over the study period in patients with a 50% decrease of proteinuria (mg/day)

From: Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study

Patient CRF number Baseline Entry Cycle 4 Cycle 6 Cycle 9
9 2,100 6,800 1,800 n.a. 1,782
10 3,600 20,880 10,710 1,572 15,576
13 2,500 3,022 1,073 2,793  
16 360 1,130 1,240 300 230
19 1,000 2,200 1,700 n.a. 1,000
26 120 5,180 800 700  
31 1,900 3,920 3,200 1,800 10,800
34 300 3,800 900 1,360 270
35 630 2,000 240 160 480
36 1,680 1,700 770 700 340
39 1,976 n.a. 2,274 2,331 1,058
49 1,700 4,600 2,800 2,900 2,360
50 5,000 11,200 750 2,770 6,401
  1. CRF, case report form.